508225340 11/13/2023

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT8272529

NATURE OF CONVEYAI	NCE:					
		ASSIGNMENT	ASSIGNMENT			
CONVEYING PARTY D	ΑΤΑ					
		Name	Execution Date			
GUANGZHOU INSTITU	TE OF BIO	MEDICINE AND HEALTH, CHINESE	11/13/2023			
ACADEMY OF SCIENC	ES "GIBH"					
RECEIVING PARTY DA	ТА					
Name:						
Street Address:	8TH FL,	FL, 15TH BLD, LEDY CAMPUS, NO.188 KAIYUAN AVE, HUANGPU				
City:	GUANGZ	(HOU				
State/Country:	CHINA					
Postal Code:	510530	10530				
PROPERTY NUMBERS	Total: 3					
Property Type		Number				
Patent Number:93		371305				
Patent Number: 97		63914				
Patent Number:	97	770432				
CORRESPONDENCE D	ата					
Fax Number:						
Correspondence will b		he e-mail address first; if that is unsu if that is unsuccessful, it will be sent				
		lefile@harnessip.com				
		ARNESS, DICKEY & PIERCE, PLC				
		700 BONHOMME, SUITE 400				
Address Line 4:	S	AINT LOUIS, MISSOURI 63105				
ATTORNEY DOCKET NU	JMBER:	19179-500001				
NAME OF SUBMITTER:		KISUK LEE				
SIGNATURE:		/Kisuk Lee/				
DATE SIGNED:		11/13/2023				
Total Attachments: 4						
source=Assignment_GIBI						
source=Assignment_GIBI	_					
	🗕 InflamaX	C 20231113EF#page3.tif				

WHEREAS, Guangzhou Institute of Biomedicine and Health, Chinese Academy Of Sciences "GIBH" 190 Kaiyuan Avenue, Science Park, Guangzhou 510530 China (hereinafter "Assignor") owns all right, title and interest in:

 PCT/CN2012/079968 filed 10 August 2012, claiming priority to CN201210202059.X filed 18 June 2012, and all patents and patent applications originated from PCT/CN2012/079968 as identified in "Exhibit A"

WHEREAS, InflamaX Pharmaceuticals Limited (安炎达医药技术(广州)有限公司), 8th FI, 15th Bld, Ledy Campus, No.188 Kaiyuan Ave, Huangpu, Guangzhou 510530, China (hereinafter "Assignee") is desirous of acquiring all right, title, and interest therein:

NOW, THEREFORE, for good and valuable consideration, the receipt and adequacy whereof is hereby acknowledged, Assignor hereby confirms any prior assignment to Assignee, and to the extent that Assignor has not already done so, agrees to assign, and hereby does, sell, assign and transfer unto Assignee and its successors in interest, the full and exclusive right, title and interest in the United States of America and throughout the world, including the right to claim priority under the laws of the United States, the Paris Convention, and any foreign countries, to the inventions as described in each of the aforesaid applications, to each of the aforesaid applications themselves, and all divisions, continuations, continuations-in-part, or other applications claiming priority directly or indirectly from the aforesaid application(s), and any United States or foreign Letters Patent, utility model, or other similar rights which may be granted thereon, including reissues, reexaminations and extensions thereof, and all copyright rights throughout the world in the aforesaid applications and patents and the subject matter disclosed therein, these rights, title and interest to be held and enjoyed by Assignee to the full end of the term for which the Letters Patent, utility model, or other similar rights, are granted and any extensions thereof as fully and entirely as the same would have been held by Assignor had this assignment and sale not been made, and the right to sue for, and recover for past infringements of, or liabilities for, any of the rights relating to any of the applications, patents, utility models, or other similar rights, resulting therefrom, and the copyright rights.

Assignor hereby covenants and agrees to execute all instruments or documents required or requested for the making and prosecution of any applications of any type for patent, utility model, or other similar rights, and for copyright, in the United States and in all foreign countries including, but not limited to, any provisional, continuation, continuation-in-part, divisional, renewal or substitute thereof, any derivation proceedings relating thereto, and as to Letters Patent any supplemental examination, derivation proceeding, opposition, post grant review, reissue, re-examination, inter partes review, or extension thereof, and for litigation regarding, or for the purpose of defending the validity of or protecting title to the said invention, the United States application for patent, or Letters Patent therefor, and to testify in support thereof, for the benefit of Assignee and its successors in interest without further or other compensation than that above set forth.



Assignor hereby covenants that no assignment, sale, license, agreement or encumbrance has been or will be entered into which would conflict with this Assignment. Assignor further covenants not to challenge, or assist or participate in any third party challenge to, the assigned inventions, or any patent application or patent thereon, whether by litigation, post grant review, inter partes review, covered business method review, reexamination, or otherwise.

Assignor hereby requests the United States Patent and Trademark Office to issue the Letters Patent of the United States of America to Assignee, and requests that any official of any country or countries foreign to the United States, whose duty it is to issue or grant patents and applications as aforesaid, to issue the Letters Patent, Utility Model Registration or other similar right to Assignee.

The undersigned hereby grants the law firm of Harness, Dickey & Pierce, P.L.C. the power to insert on this Assignment any further identification which may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office for recordation of this document.

Guangzhou Institute of Biomedicine and Health, Chinese Academy Of Sciences "GIBH" 190 Kai Yuan Avenue, Science Park...Guangzhou, ş.ĭ

China 510530

Signature

Printed Name : <u>Duan Ziyuan</u>

Title: Legal Kepresontalive

. 11.13

Witness Signature

Date

<u>Chen Longh</u>

Witness Signature

Date

Date

Printed Name

Page 2 of 4

Exhibit A. Patents and Patent Applications originated from PCT/CN2012/079968

Country	Application No.	Filing Date	Patent No.	Issue Date
United States of America	14/401600	17-Nov-2014	9371305	21-Jun-2016
United States of America	15/182496	14-Jun-2016	9763914	19-Sep-2017
Japan	2015516409	04-Dec-2014	6227635	20-Oct-2017
Canada	2875721	04-Dec-2014	2875721	06-Jul-2021
United States of America	15/182525	14-Jun-2016	9770432	28-Sep-2017
Albania	128792405	04-Dec-2014	2845854	21-Sep-2016
Austria	128792405	04-Dec-2014	2845854	21-Jun-2016
Belgium	128792405	04-Dec-2014	2845854	21-Sep-2016
Bulgaria	128792405	04-Dec-2014	2845854	21-Sep-2016
Switzerland	128792405	04-Dec-2014	2845854	21-Sep-2016
Cyprus, Republic of	128792405	04-Dec-2014	2845854	21-Sep-2016
Czech Republic	128792405	04-Dec-2014	2845854	21-Sep-2016
Germany	128792405	04-Dec-2014	6020120234121	21-Sep-2016
Denmark	128792405	04-Dec-2014	2845854	21-Sep-2010
Estonia	128792405	04-Dec-2014	2845854	21-Sep-2016
Spain	128792405	04-Dec-2014	2845854	21-Sep-2016
Finland	128792405	04-Dec-2014	2845854	21-Sep-2010
France	128792405	04-Dec-2014	2845854	21-Sep-201i
United Kingdom	128792405	04-Dec-2014	2845854	21-Sep-2010
Greece	128792405	04-Dec-2014	2845854	21-Sep-201
Croatia	128792405	04-Dec-2014	2845854	21-Sep-201
Hungary	128792405	04-Dec-2014	E031172	21-Sep-201
ireland	128792405	04-Dec-2014	2845854	21-Sep-201

Page 3 of 4

Iceland	128792405	04-Dec-2014	2845854	21-Sep-2016
Italy	128792405	04-Dec-2014	502016000126751	21-Sep-2016
Lithuania	128792405	04-Dec-2014	2845854	21-Sep-2016
Luxembourg	128792405	04-Dec-2014	2845854	21-Sep-2016
Latvia	128792405	04-Dec-2014	2845854	21-Sep-2016
Monaco	128792405	04-Dec-2014	2845854	21-Sep-2016
North Macedonia	128792405	04-Dec-2014	906987	21-Sep-2016
Malta	128792405	04-Dec-2014	PT347702845854	21-Sep-2018
Netherlands	128792405	04-Dec-2014	2845854	21-Sep-2016
Norway	128792405	04-Dec-2014	2845854	21-Sep-2016
Poland	128792405	04-Dec-2014	2845854	21-Sep-2016
Portugal	128792405	04-Dec-2014	2845854	21-Sep-2016
Romania	128792405	04-Dec-2014	2845854	21-Sep-2016
Serbia	128792405	04-Dec-2014	2845854	21-Sep-2016
Sweden	128792405	04-Dec-2014	2845854	21-Sep-2016
Slovenia	128792405	04-Dec-2014	2845854	21-Sep-2016
Slovakia	128792405	04-Dec-2014	2845854	21-Sep-2016
San Marino	128792405	04-Dec-2014	2845854	21-Sep-2016
Turkiye	128792405	04-Dec-2014	201617586	21-Sep-2016

Page 4 of 4